
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp showcases a promising future driven by a robust clinical pipeline of investigational therapeutics targeting various neurodegenerative and rare diseases, particularly with its programs like NEOD001 for amyloidosis and PRX002 for Parkinson's disease. The company has guided that it could potentially earn up to $105 million in aggregate milestones by 2026, translating to approximately $2 per basic share outstanding, through partnerships with major pharmaceutical companies such as Novo Nordisk and Bristol-Myers Squibb. Additionally, despite some concerns regarding elevated ARIA incidence in PRX012-treated patients, the overall data indicates a favorable reduction in amyloid levels, alongside the therapy being well-tolerated with low incidence of injection-site reactions.
Bears say
Prothena Corp PLC faces a negative outlook primarily due to its ongoing net losses, which are expected to persist until product approval and likely through the initial commercialization phase. The company is anticipated to require additional capital in the short term to continue developing its drug candidates, raising concerns about potential dilution of shareholder value. Moreover, regulatory and clinical risks present uncertainties that could further complicate the approval processes for its investigational therapeutics, adding to the financial challenges ahead.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares